A literature review of 2019 Novel Coronavirus during the early outbreak period: Epidemiology, causes, clinical manifestation and diagnosis, prevention and control

Sasmita Poudel Adhikari¹, Sha Meng¹, Yuju Wu¹, Yuping Mao², Ruixue Ye¹, Qingzhi Wang¹, Chang Sun¹, Sean Sylvia³, Scott Rozelle⁴, Hein Raat⁵ and Huan Zhou¹,*

¹West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China; ssmtpoudel@gmail.com (S.P.A.), 15003415649@163.com (S. M.), uuuqianjin@163.com (Y.W.), yueruixue1021@163.com (R.Y.), 13183812895@163.com (Q.W.), changsun233@163.com (C.S.), zhouhuan@scu.edu.cn (H.Z.)
²Department of Communication Studies, California State University, Long Beach, CA 90802, USA; yuping.mao@csulb.edu
³Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; sylvia@arec.umd.edu
⁴Freeman Spogli Institute for International Studies, Stanford University, California, USA; rozelle@stanford.edu
⁵Department of Public Health, Erasmus MC—University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands; h.raat@erasusmc.nl

* Correspondence: zhouhuan@scu.edu.cn; Tel.: 86-28-8550-1548

Abstract: The 2019-nCoV has been identified as the cause of an outbreak of respiratory illness in Wuhan, Hubei Province, China beginning in December 2019. This epidemic had spread to 19 countries with 11,791 confirmed cases, including 213 deaths, as of January 31, 2020. The World Health Organization declared it as a Public Health Emergency of International Concern. This study analyzed and discussed 70 research articles published until January 31, 2020 for a better understanding of the epidemiology, causes, clinical diagnosis, prevention and control of this virus. Studies thus far have shown origination in connection to a seafood market in Wuhan, but specific animal association has not been confirmed. The reported symptoms include fever, cough, fatigue, pneumonia, headache, diarrhea, hemoptysis, and dyspnea. Preventive measures such as masks, hand hygiene practices, avoidance of public contact, case detection, contact tracing, and quarantines are effective for reducing the transmission. To date, no specific antiviral treatment is proven effective, hence, infected people primarily rely on symptomatic treatment and supportive care. Although these studies had relevance to control a public emergency, more research need to be conducted to provide valid and reliable ways to manage this kind of public health emergency in both short- and long-term.

Keywords: 2019-nCoV, epidemiology, causes, prevention and control, review

1. Introduction

The Coronavirus belongs to the family of virus that causes viral pneumonia including fever, breathing difficulty, and lung infection [1]. These viruses are common in the animals worldwide, but very few cases of them are known to affect humans. The World Health Organization (WHO) used the term 2019 novel coronavirus (2019-nCoV) to refer to the coronavirus that was diagnosed from the lower respiratory tract of patients with pneumonia in Wuhan, China on 29 December, 2019 [2-4]. It is believed that the human infection of the virus originated from the local Huanan South China Seafood Market in Wuhan, Hubei Province, China [5]. Consequently, Chinese Center for Disease Control and Prevention (China CDC) dispatched a rapid response team to accompany Hubei provincial and Wuhan city health authorities to conduct epidemiological and etiological investigations. The WHO reported that the outbreak of coronavirus epidemic was associated with
the marketplace, but no specific animal association has been identified [6]. Scientists immediately started to research the source of coronavirus. The first genome of 2019–nCoV was published by the research team led by Prof. Yong-Zhen Zhang, on January 10, 2020 [7]. Within one month, this virus spread quickly throughout China and globally during the Chinese New Year when there is high level of human mobility among Chinese. Although it is still early to predict the susceptible population, early patterns have shown a similar trend with Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus, showing associations with age, biological sex and other health conditions [8]. 2019-nCoV has now been declared as Public Health Emergency of International Concern by WHO [9].

Given the quick and widespread of coronavirus and its severe impacts on human health, the research community has responded rapidly to the new virus and many preliminary research articles have already been published about this epidemic (Appendix Table). We conducted a review of all the published scientific articles on coronavirus in January 2020. This review aims to provide a summary and critical analysis of early findings on epidemiology, causes, clinical diagnosis, prevention and control of 2019-nCoV. This review can provide meaningful information for future research related to the topic and government decision-making on strategies to battle this public health emergency at community, national and international level.

2. Materials and Methods

2.1 Literature search

Literatures for this review were identified by searching the following online databases: bioRxiv, medRxiv, ChemRxiv, Google scholar, Pubmed, as well as CNKI and Wan Fang (the two primary databases for biomedical research in mainland China). These online databases contain archives of most English and Chinese biomedical journals. In addition, some white papers published online by the National Health Commission of China, National Center of Disease Prevention and Control, and WHO were also searched and included in the analysis. We searched scientific publications from 1 January to 31 January 2020. The search terms were ‘nCoV’, ‘2019 novel coronavirus’, ‘2019-nCoV’, ‘novel coronavirus’, ‘Pneumonia’, ‘新型冠状病毒’, ‘新型肺炎’, and ‘新冠病毒’. We included all the relevant scientific publications written in English or Chinese in the review. Commentary, reports and news articles were excluded from the analysis.

Two researchers, searched the literatures independently. The two sets of literature were compared. Disagreements on inclusion or exclusion of literature were resolved through discussion or, if necessary, through a third review adjustment. Duplicate articles were eliminated. Eventually, 70 unique academic publications were included in this analysis (Appendix Table). Figure 1 presents a flow diagram showing the process of searching and selecting the research articles.

2.2 Data analysis

Articles were classified into four research domains: epidemiology, causes, clinical manifestation and diagnosis, prevention and control. The research domains, published dates, journal language, and authors’ affiliations were analyzed respectively.

3. Results and discussion

3.1 Characteristics of published studies

Among the 70 research articles included in the analysis, more than 30 were on preprint servers, and 36 are published in peer-reviewed journals, including The Lancet and the New England Journal of Medicine. Most of the publications (n=60, 85.71 %) are in English and few (n=10, 14.29 %) are in Chinese (Table 1).
English literatures identified through database searching in:
- bioRxiv (n=26)
- medRxiv (n=4)
- ChemRxiv (n=1)
- Google scholar (n=67)
- Pubmed (n=28)

Chinese literatures identified through database searching in:
- CNKI (n=8)
- Wan Fang (n=6)

Records after duplicates remove (n=135)

Records screened title and abstract (n=135)

Excluded based on criteria for title & abstract (n=11)

Full-text articles screened (n=124)

Excluded Comments (n=21)
- News (n=28)
- Reports (n=2)
- Guideline (n=3)

Full-text articles ready for analysis (n=70)

Figure 1: Flow diagram for selection process of articles

Table 1: Breakdown of 2019-nCoV research articles by language (published in January 2020)

| Research Domains                | English literature | Chinese literature | Total |
|----------------------------------|--------------------|--------------------|-------|
|                                  | n                  | %                  | n     | %    | n    | %    |
| Epidemiology                     | 20                 | 33.33              | 0     | 0    | 20   | 28.57 |
| Causes                           | 25                 | 41.67              | 1     | 10   | 26   | 37.14 |
| Clinical manifestation and diagnosis| 7                 | 11.67              | 2     | 20   | 9    | 12.86 |
| Prevention and control           | 8                  | 13.33              | 7     | 70   | 15   | 21.43 |
| **Total**                        | **60**             | **85.71**          | **10**| **14.29** | **70** | **100** |

Academic publications are distributed across the following research domains: epidemiology, causes, clinical manifestation and diagnosis, as well as prevention and control. The largest portion of the papers (n=26, 37.14%) are related to causes, followed by papers on epidemiology (n=20, 28.57%), while 21.43% examined prevention and control and 12.86% reported clinical manifestations and diagnosis (Figure 2). Research articles initially focused on causes of the virus, while prevention and control studies have gradually increased over time (Figure 3). Around 80% of English language publications focus on epidemiology and causes, while 70% of Chinese papers have focused on prevention and control. The majority of the articles (n=46, 65.71%) are published by Chinese scholars whereas 30% (n=21) articles are from scholars outside of China, and few (n=3, 14.29 %) are based on collaborative research by scholars from different countries (Table 2).
Table 2: Breakdown of 2019-nCoV research articles by type of collaboration

| Research domains                          | Inside China | Outside China | International Collaboration | Total |
|-------------------------------------------|--------------|---------------|-----------------------------|-------|
| **n**                                     | **%**        | **n**         | **%**                       | **n** |
| Epidemiology                              | 8            | 9             | 3                           | 20    |
| Causes                                    | 17           | 9             | 0                           | 26    |
| Clinical manifestation and diagnosis      | 8            | 1             | 0                           | 9     |
| Prevention and control                    | 13           | 2             | 0                           | 15    |
| **Total**                                 | **46**       | **21**        | **3**                       | **70**|
3.2 Research domains

3.2.1 Epidemiology

On 29 December 2019, the first four cases of an acute respiratory syndrome of unknown etiology among people linked to a seafood market (“wet market”) were reported in Wuhan city, Hubei province, China [4]. Research is underway to understand more about transmissibility, severity, and other features associated with 2019-nCoV [2]. It appeared most of the early cases had contact history with the original seafood market [4, 10-12]. Soon, the secondary source of infection was found to be human-to-human transmission among close contacts. There was an increase of infected people with no history of exposure to wildlife or visiting Wuhan, and multiple cases of infection were detected among medical professions [4, 12-15]. The 2019-nCoV infection occurs through exposure to the virus, and both the immunosuppressed and normal population appear susceptible. Some studies have reported an age distribution of adult patients between 25 and 89 years old. Most adult patients are between 35 and 55 years old. There are fewer identified cases among children and infants [12, 16]. A study on early transmission dynamics of the virus reports the median age of patients to be 59 years, ranging from 15 to 89 years, with the majority (59%) being male [4]. Research suggest that the population at most risk may be people with poor immune function such as older people and people with renal and hepatic dysfunction [4].

Different public health measures were applied to prevent or slow down the transmission of the 2019-nCoV. Specific public health measures include case isolation, identification and follow-up of contacts, environmental disinfection, and use of personal protective equipment’s [17]. The 2019-nCoV has been found to have higher levels of transmissibility and pandemic risk than the SARS-CoV as the effective reproductive number (R) of 2019-nCoV (2.9) is higher than the effective R of SARS (1.77) at the early stage [13]. The average incubation duration of 2019-nCoV were reported to be 4.8±2.6, ranging from 2-11 days [13] and 5.2 days (95 % Confidence interval , 4.1 to 7) [4]. The latest guidelines from Chinese health authorities reported an average incubation duration of 7 days, ranging from 2-14 days [18].

In China, 11,791 cases were confirmed and 17,988 were suspected cases in 34 provinces as of 24:00, January 31, 2020 (Figure 4) [19]. The 2019-nCoV quickly spread to several other countries after its outbreak in China including 213 deaths globally [20]. Confirmed cases were reported in the following 19 countries outside of China: Australia (9), Canada (3), Cambodia (1), France (6), Finland(1), Germany (5), India (1), Italy (2), Japan (14), Nepal (1), Malaysia (8), Philippines (1), Republic of Korea (11), Singapore (13), Sri Lanka (1), Thailand (14), United States of America (6), United Arab Emirates(4) and Vietnam (5) (Figure 5) [20].

3.2.2 Causes

3.2.2.1 Virology and Pathogenesis

Coronaviruses are enveloped single-stranded RNA viruses that are zoonotic in nature and cause symptoms ranging from those similar to the common cold to more severe respiratory, enteric, hepatic and neurological symptoms [5, 21]. Other than 2019-nCoV, there are six known coronaviruses in human: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1 and MERS-CoV [2, 18, 22, 23]. Coronavirus has caused two large scale pandemics in the last two decades: SARS [24] and MERS [10, 25].

To detect the infection source of 2019-nCoV, the China CDC researchers collected 585 environmental samples from the Huanan Seafood Market in Wuhan, Hubei Province, China on January 1 and January 12, 2020. They detected 33 samples containing 2019-nCoV and indicated that it originated from wild animals sold in the market [26]. Then, researchers used the lung fluid, blood, and throat swab samples of 15 patients to conduct laboratory tests. These laboratory tests found the virus-specific nucleic acid sequences in the sample, which has a different coronavirus-specific nucleic acid sequences from known human coronavirus species. Laboratory results also indicated
that 2019-nCoV is similar to some of the beta (β) coronaviruses genera identified in bats [10, 16, 27], which is situated in a group of SARS/ SARS-like CoV [10].

Figure 4: Distribution of 2019-nCoV cases in China [19]

Figure 5: Global distribution of 2019-nCoV cases [20]
To conduct next-generation sequencing from bronchoalveolar lavage fluid and cultured isolates, researchers enrolled nine inpatients with viral pneumonia and negative in common respiratory pathogens in Wuhan. The results of this next-generation sequencing indicated that 2019-nCoV was more distant from SARS-CoV (with about 79% sequence identity) and MERS-CoV (with about 50% sequence identity) than from two bat-derived SARS-like coronaviruses—bat-SL-CoVZC45 (with 87.99% sequence identity) and bat-SL-CoVZXC21 (with 87.23% sequence identity) [28]. Studies also reported that 2019-nCoV S-protein supported strong interaction with human ACE2 molecules despite its sequence diversity with SARS-CoV [10, 29].

3.2.2.2 Transmission pattern

Many domestic and wild animals, including camels, cattle, cats, and bats, serves as hosts for coronaviruses [18]. Generally, animal coronaviruses do not spread among human beings. However, there are exceptions, such as SARS and MERS, which were mainly spread through close contact with infected people via respiratory droplets from cough or sneezing. With regards to 2019-nCoV, early patients had some link to the Huanan Seafood Market in Wuhan, China, suggesting that these early infections were due to animal-to-person transmission. Soon, more cases emerged among medical staff and others with no history of exposure to that market or visiting Wuhan, which indicate human-to-human transmission [4, 13-15].

According to the latest guidelines from Chinese health authorities [18, 30], 2019-nCoV has three main transmission routes: 1) direct transmission, 2) aerosol transmission, 3) contact transmission. Direct transmission occurs when respiratory droplets (as produced when an infected person coughs or sneezes) are ingested or inhaled by individuals nearby in close proximity (about 6 feet); Aerosol transmission occurs when respiratory droplets mix into the air, forming aerosols and causing infection when inhaled into the lungs; and Contact transmission occurs when a subject touches a surface or object contaminated with the virus. Individuals could be infected when they subsequently touch their mouth, nose, or, possibly, eyes.

In addition to these three routes, one study also indicated the digestive system as a potential transmission route for 2019-nCoV infection. Since patients had abdominal discomfort and diarrhea symptoms, researchers analyzed 4 datasets with single-cell transcriptomes of digestive system and found that ACE2 was highly expressed in absorptive enterocytes from ileum and colon [31].

3.2.3 Clinical manifestation and diagnosis

The complete clinical manifestation is not clear yet, as symptoms range from mild to severe, sometimes even resulting in death [2]. The most commonly reported symptoms are fever, cough, myalgia or fatigue, pneumonia and complicated dyspnea, whereas less common symptoms include headache, diarrhea, hemoptysis, runny nose, and phlegm-producing cough [2, 14]. Patients with mild symptoms usually recovered after 1 week while severe cases might experience progressive respiratory failure due to alveolar damage from the virus, which may lead to death [11]. Cases resulting in death were primarily middle-aged and elderly patients with pre-existing diseases (tumor surgery, cirrhosis, hypertension, coronary heart disease, diabetes, and Parkinson's disease) [11]. Case definition guidelines include the following symptoms: fever, decrease in lymphocytes and white blood cells, new pulmonary infiltrates on chest radiography, and no improvement in symptoms upon three days of antibiotics treatment [4].

For patients with suspected infection, the following procedures are suggested for diagnosis: performing real-time fluorescence RT-PCR to detect the positive nucleic acid of 2019-nCoV in sputum, throat swabs, and secretions of the lower respiratory tract samples [11, 12, 30]. To date, no specific antiviral treatment has been confirmed to be effective. Therefore, infected patients with 2019-nCoV are treated by symptomatic and supportive care [2, 14].
3.3.4 Prevention and Control

Prevention and control strategies and methods are reported at three levels: national level, case-related population level, and general population level. At the national level, the National Health Commission of the People’s Republic of China issued the “No.1 announcement” on January 20, 2020, which officially included the 2019-nCoV into the management of class B legal infectious diseases, and allowed for class A infectious diseases preventive and control measures to be implemented [32]. Under this policy, medical institutes can adopt isolation treatment and observation protocols to prevent and control the spread of the 2019-nCoV. On January 22nd, 2020, the National Health Commission published national guidelines for the prevention and control of 2019-nCoV for medical institutes to prevent the nosocomial infection [33]. On January 28, 2020, the National Health Commission issued protocols for rapid prevention and control measures in order to effectively contain the spread of epidemic through a “big isolation and big disinfection” during the Chinese Spring Festival [34]. National-level strategies have also been issued with targeted measures for rural areas (issued on January 28, 2020) and the elderly population (issued on January 31, 2020) [35, 36].

Studies have also explored the prevention of nosocomial infection and psychological health issues associated with the 2019-nCoV. A series of measures have been suggested to reduce nosocomial infection, including knowledge training for prevention and control, isolation, disinfection, classified protection at different degrees in infection areas, and protection of confirmed cases [16, 37, 38]. Concerning psychological health, some suggested psychological intervention for confirmed cases, suspected cases, and medical staffs [16, 39].

For the general population, there is no vaccine preventing 2019-nCoV. The best prevention is to avoid being exposed to the virus [40]. Airborne precautions and other protective measures are useful for prevention. Infection preventive and control (IPC) measures that reduce the risk of exposure include: Preventive measures that can reduce the risk of exposure include the following: use of face masks, covering coughs and sneezes with tissues or flexed elbow that are then safely disposed of; regular hand washing with soap or disinfection with hand sanitizer containing at least 60% alcohol (if soap and water is not available); avoidance of contact with infected people and keeping the distance as much as possible (at least 1 meter); and the refrain from touching the eyes, nose, and mouth with unwashed hands [2]. The detail advice on the use of face masks at the community, during care at home and in the healthcare settings in 2019-nCoV is given by the WHO [41]. Health care workers are recommended to use the particulate respirator such as certified N95 or FFP2 when performing aerosols generating procedures, and use medical masks while providing any care to suspected or confirmed cases. Individuals with respiratory symptoms are advised to use medical masks both at the health care settings and home care properly following the infection prevention guidelines. At the community, individual without respiratory symptoms do not require a medical mask but if coughing and sneezing should cover nose and mouth with tissues or flexed elbow and perform regular hand hygiene. Proper use and disposal of masks are important to avoid any increase in risk of transmission [41]. In addition to articles published in research journals, the China CDC published a guideline to raise awareness of the prevention and control of 2019-nCoV among the general population. This guideline contains plenty information on the 2019-nCoV itself and its prevention. The key contains of the guideline include the following: the causes of 2019-nCoV, how to choose and wear face masks, proper hand washing habits, preventive measures at different locations (e.g., at home, on public transportation, and in public space), disinfection methods, and medical observation at home [42]. In addition to scientific knowledge on ways to battle 2019-nCoV, the guideline also introduces ways to eliminate panic among the general population [42].

4. Conclusions

There has been a rapid surge in research in response to the outbreak of 2019-nCoV. During this early period, studies have been published exploring the epidemiology, causes, clinical manifestation and diagnosis, prevention and control of the novel coronavirus. Thus far, most studies have focused
on the epidemiology and causes. Studies exploring prevention and control measures have begun to gradually increase. Studies providing evidence on prevention and control measures are urgently needed to minimize the impact of the outbreak. Government agencies have quickly incorporated recent scientific findings into public policies at community, regional, and national levels to slow down and/or prevent the further spread of the 2019-nCoV.

**Author Contributions:** Conceptualization, Sasmita Poudel Adhikari, and Huan Zhou; methodology, Qingzhi Wang, Sha Meng, Ruixue Ye, Yujun Wu, Chang Sun; formal analysis, Qingzhi Wang, Sha Meng, Sasmita Poudel Adhikari, and Huan Zhou; writing—original draft preparation, Sasmita Poudel Adhikari and Huan Zhou; writing—review and editing, Sasmita Poudel Adhikari, Huan Zhou, Sean Silvia, Yuping Mao, Scott Rozelle and Hein Raat. All authors have read and agreed to the final submitted version of the manuscript for publications.

**Funding:** This research was funded by China Medical Board (CMB-18-297).

**Acknowledgments:** Our sincere thanks go to all the experts who have insights to this paper.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Appendix A**

Appendix 1: Published research articles on 2019-nCoV in January, 2020 (submitted in separate file).

**References**

1. WMHC. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020, http://wjw.wuhan.gov.cn/front/web/ showDetail/2019123108989 (accessed on 1 February 2020).

2. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.S.M.; Lau, E.H.Y.; Wong, J.Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Li, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T.T.Y.; Wu, J.T.K.; Gao, G.F.; Cowling, B.J.; Yang, B.; Leung, G.M.; Feng, Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. The New England Journal of Medicine 2020, DOI: 10.1056/NEJMoa2001316.

3. CDC. 2019 Novel Coronavirus, Wuhan, China. https://www.cdc.gov/coronavirus/2019-nCoV/summary.html (accessed on 1 February 2020).

4. WHO. Novel Coronavirus–China. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ (accessed on 1 February 2020).

5. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Ni, P.; Zhan, F.; Ma, Z.; Wang, D.; Zu, W.; Wu, G.; Gao, G.F.; Tan, W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 2020, DOI: 10.1056/NEJMoa2001017.

6. WHO. Novel Coronavirus–Japan (ex-China). https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/ (accessed on 1 February 2020).

7. Virological.org. Novel 2019 Coronavirus—Genome. http://virological.org/t/novel-2019-coronavirus-genome/319 (accessed on 1 February 2020).

8. Fehr, A.R.; Channappanavar, R.; Perlman, S. Middle East respiratory syndrome: emergence of a pathogenic human coronavirus. Annual review of medicine 2017, 68, 387-99.

9. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCOV) (accessed on 1 February 2020).

10. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chne, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X.; Zheng, X.S.; Zhao, K.; Chen, Q.J.; Deng, F.; Liu, L.L.; Yan, B.; Zhan, F.Z.; Wng, Y.Y.; Ziao, G.; Shi, Z.L. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. doi: https://doi.org/10.1101/2020.01.22.914952.
11. Li, T.; Wei, C.; Li, W.; Hongwei, F.; Shi, J. Beijing Union Medical College Hospital on “pneumonia of novel coronavirus infection” diagnosis and treatment proposal (V2.0). Medical Journal of Peking Union Medical College Hospital. 2020, http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html (accessed on 2 Feb 2020).

12. Medical expert group of Tongji hospital. Quick guide to the diagnosis and treatment of pneumonia for novel coronavirus infections (third edition). Herald of Medicine. 2020. http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html (accessed on 2 February 2020).

13. Liu, T.; Hu, J.; Kang, M.; Lin, L.; Zhong, H.; He, G.; Song, T.; Huang, Q.; Rong, Z.; Deng, A.; Zeng, W.; Tan, X.; Zeng, S.; Zhu, Z.; Li, J.; Wan, D.; Lu, J.; Deng, H.; He, J.; Ma, W.E. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). 2020, doi: https://doi.org/10.1101/2020.01.25.919767

14. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, Y.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020, https://doi.org/10.1016/S0140-6736(20)30183-5.

15. Gralinski, L.E., Menachery, V.D. Return of the Coronavirus: 2019-nCoV. Viruses 2020, 12, 135, https://doi.org/10.3390/v12020135

16. Wang, C.; Wang, X. Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection. Chinese General Practice Nursing 2020, 18, 2-3. doi:10.12104/j.issn.1001-0164.2020.03.02

17. Wei, Q.; Ren, Z. Disinfection measures for pneumonia foci infected by novel coronavirus in 2019. Chinese journal of Disinfection 2020, 37, 59-62. doi:10.11762/j.issn.1001-7658.2020.01.019

18. National Health Commission C. Prevent guideline of 2019-nCoV. http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml (accessed on 1 February 2020).

19. National Health Commission of China. An update on the incidence of pneumonia with novel coronavirus infection as at 24:00 on 31 January 2020. http://www.nhc.gov.cn/xcs/yqfkdt/202002/84afa71e09644646f4b1ae44939ba5c528.shtml (accessed on 1 February 2020).

20. WHO. Novel Coronavirus (2019-nCoV) Situation Report–11. 2020 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7d07_4 (accessed on 1 February 2020).

21. WHO. Coronavirus. https://www.who.int/health-topics/coronavirus (accessed on 1 February 2020).

22. Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A.C.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in microbiology 2016, 24, 490-502.

23. Chen, Y.; Liu, Q.; Guo, D. Coronaviruses: genome structure, replication, and pathogenesis. Journal of Medical Virology, 2020, https://doi.org/10.1002/jmv.25681.

24. Peiris, J.S.M.; Guan, Y.; Yuen, K. "Severe acute respiratory syndrome. Nature medicine 2004, 10, S88-S97. DOI: 10.1038/NEJMra032498.

25. Zaki, A.M.; Van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine 2012, 367, 1814-1820. DOI: 10.1056/NEJMoa1211721.

26. Chinese Center for Disease Control and Prevention detected 585 environmental samples from the South China Seafood Market in Wuhan, Hubei Province, China. http://www.chinacdc.cn/yyw_9324/202001/t20200127_211469.html (accessed on 1 February 2020).

27. Lu, H.; Tang, C.; Tang, Y. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. 2020. Journal of Medical Virology DOI: https://doi.org/10.1002/jmv.25678.

28. Roujjan, L.; Zhao, X.; Li, J.; Ni, P.; Yang, B.; Wu, H.; Wnag, W.; Song, H.; Huang, B.; Zhu, A.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Zie, Z.; Gao, G.F.; Wu, G.; Chen, W.; Shi, W.; Tan, W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet 2020, https://doi.org/10.1016/S0140-6736(20)30251-8

29. Xu, X.; Chen, P.; Wang, J.; Feng, J.; Zhou, H.; Li, X.; Zhong, W.; Hao, P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. SCIENCE CHINA Life Sciences 2020, https://doi.org/10.1007/s11427-020-1637-5

30. National Health Commission, China. Pneumonia diagnosis and treatment of 2019-nCoV infection from Chinese NHC and CDC 2020
31. Zhang, H.; Kang, Z.; Gong, H.; Xu, D.; Wang, J.; Li, Z.; Cui, X.; Xiao, J.; Meng, T.; Zhou, W.; Liu, J.; Xu, H. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020, doi: http://dx.doi.org/10.1101/2020.01.30.927806.

32. National Health Commission, China. Pneumonia infected with novel coronavirus is included in the management of legal infectious diseases. http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8d367901d4f33.shtml (accessed on 31 January, 2020)

33. National Health Commission, China. Notice on printing and distributing the technical guide for prevention and control of novel coronavirus infection in medical institutions. (First Edition) http://www.nhc.gov.cn/zyyjg/s7659/202001/b91fda87c304431eb082d67847d27e14.shtml (accessed on 31 January, 2020)

34. National Health Commission, China. Notice on printing and distributing the work plan for prevention and control of pneumonia caused by novel coronavirus infection in the near future. http://www.nhc.gov.cn/tigs/s7848/202001/8086bb75e5ce415aa1974c78ddc653f.shtml (accessed on 31 January, 2020).

35. National Health Commission, China. Notice on further prevention and control of pneumonia caused by novel coronavirus infection in rural areas. http://www.nhc.gov.cn/jkj/s3578/202001/88d45f6af1d24ef18151c1d91c8a28.shtml (accessed on 31 January, 2020).

36. National Health Commission, China. Notice on prevention and control of novel coronavirus infection pneumonia in the elderly people. http://www.nhc.gov.cn/ljks/lggs/202001/9e682ba8a14d1b283da990d39771493.shtml (accessed on 31 January, 2020).

37. Bin, C.; Fang, X.; Chen, H. Application effect of disaster vulnerability analysis in coping with the transmission of new coronavirus in non-closed hematology ward. http://kns.cnki.net/kcms/detail/14.1272.R.20200131.1909.002.html. (accessed on 2 Feb 2020).

38. Wei, Q.; Ren, Z. Disinfection measures for pneumonia foci infected by novel coronavirus in 2019. Chinese journal of Disinfection 2020, 37, 59-62. doi:10.11762/j.issn.1001-7658.2020.01.019

39. Xu, M.; Zhang, Y. Investigation on the psychological status of the first batch of clinical first-line support nurses to fight against pneumonia caused by novel coronavirus. Chinese Nursing Research 2020, 34, 1-3. doi: 10.12102/j.issn.1009-6493. 2020. 03. 001

40. Ou, F.; Wu, H.; Yang, Y.; Tan, W., Zhang, J.; Gu, J. Countermeasures for rapid spread of new coronavirus pneumonia in Wuhan. Chinese General Practicing Nursing. 2020. http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html. (accessed on 2 February 2020)

41. WHO. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus 2019-nCoV outbreak (Interim guidance) WHO/nCoV/IPC_Masks/2020.1 (accessed on 3 February 2020)

42. National Health Commission, China. Guidelines for public protection against novel coronavirus infection. http://www.nhc.gov.cn/jkj/s7915/202001/bc661e49b5bc487dba182f5e49ac445b.shtml (accessed 31 January, 2020)